Ranitidine duty suspension
Executive Summary
Subject of Sept. 24 hearing by Ways & Means/Trade Subcommittee will be legislation (HR 3130) temporarily suspending duty on ranitidine hydrochloride, the active ingredient in Glaxo's Zantac. Witnesses will include Glaxo and SmithKline Beecham. Glaxo maintains that the duty suspension would result in loss of Treasury revenues of $7-$9 mil. per year, based on CBO figures.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.